Once in a Blue Moon Academia (OBMA)

  Piramal’s Supradyn: Illusory Vitality and Expensive Urine Posted on 2nd October, 2025 (GMT 07:10 hrs) ABSTRACT This communication critically examines Piramal Pharma’s over-the-counter multivitamin supplement Supradyn, highlighting concerns of pharmacological redundancy, cumulative risks, and misleading advertising. While promoted as a universal “energy booster,” Supradyn’s formulation—comprising multiple water- and fat-soluble vitamins, trace minerals, and herbal additives like ginseng—offers limited physiological benefit for healthy adults: water-soluble vitamins are largely excreted, fat-soluble vitamins and trace minerals may accumulate to toxic levels, and ginseng poses risks of insomnia, cardiovascular effects, drug interactions, and psychiatric destabilization. Evidence from Indian and global experts underscores that routine supplementation is unnecessary in non-deficient populations, and clinical trials consistently show minimal to no outcome benefit, contrary to perc...

Piramal, Polycrol, Pesticides, and the Politics of Stomachs Posted on 30th September, 2025 (GMT 11:40 hrs) ABSTRACT This letter critically examines Polycrol, an over-the-counter antacid by Piramal Pharma, as both a medical product and a metaphor for systemic socio-economic and political injustices in India. While marketed for short-term relief of digestive discomfort, Polycrol contains aluminium compounds whose chronic ingestion poses documented neurotoxic, skeletal, renal, and haematological risks, yet long-term clinical evidence of efficacy is absent. The correspondence situates the product within broader “pharma-political” dynamics, linking corporate profiteering, regulatory laxity, celebrity endorsements, and pesticide exposure to a cultural normalization of self-medication. Drawing parallels between the symptomatic relief of Polycrol and the quick-fix, extractive logic of crony capitalism—as exemplified in the DHFL financial scandal—the letter calls for regulatory transparency...